NASDAQ:BWAY BrainsWay (BWAY) Stock Forecast, Price & News $4.22 +0.07 (+1.69%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$4.05▼$4.2550-Day Range$2.28▼$4.6152-Week Range$1.38▼$4.85Volume37,324 shsAverage Volume71,988 shsMarket Capitalization$70.05 millionP/E RatioN/ADividend YieldN/APrice Target$6.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BrainsWay MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside58.0% Upside$6.67 Price TargetShort InterestHealthy0.50% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.40) to ($0.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 starsMedical Sector576th out of 963 stocksSurgical & Medical Instruments Industry63rd out of 95 stocks 3.5 Analyst's Opinion Consensus RatingBrainsWay has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.67, BrainsWay has a forecasted upside of 58.0% from its current price of $4.22.Amount of Analyst CoverageBrainsWay has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.50% of the outstanding shares of BrainsWay have been sold short.Short Interest Ratio / Days to CoverBrainsWay has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BrainsWay has recently increased by 268.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBrainsWay does not currently pay a dividend.Dividend GrowthBrainsWay does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BWAY. Previous Next 2.5 News and Social Media Coverage News SentimentBrainsWay has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BrainsWay this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for BWAY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added BrainsWay to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BrainsWay insiders have not sold or bought any company stock.Percentage Held by Insiders19.00% of the stock of BrainsWay is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.76% of the stock of BrainsWay is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BrainsWay are expected to grow in the coming year, from ($0.40) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BrainsWay is -10.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BrainsWay is -10.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBrainsWay has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BrainsWay (NASDAQ:BWAY) StockBrainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, the Asia Pacific, Europe, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.Read More BWAY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BWAY Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for BrainsWay (NASDAQ:BWAY)September 20, 2023 | finance.yahoo.comBrainsWay Broadens Access to Deep TMS™ for U.S. Military Service Members Through Expanded Partnership with Katie’s Way PlusSeptember 26, 2023 | Altimetry (Ad)Pentagon Consultant—Here's how Biden Wins Landslide Re-election—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,September 13, 2023 | finance.yahoo.comAre Medical Stocks Lagging Brainsway (BWAY) This Year?September 13, 2023 | finance.yahoo.comAre Medical Stocks Lagging Brainsway (BWAY) This Year?September 6, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM) and Brainsway (BWAY)September 5, 2023 | finance.yahoo.comBrainsWay Forges Strategic Partnership with Treatment Provider in Northeast U.S.August 10, 2023 | msn.comBrainsWay: Profitability Is Within SightSeptember 26, 2023 | Altimetry (Ad)Pentagon Consultant—Here's how Biden Wins Landslide Re-election—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,August 9, 2023 | yahoo.comHow to Get Tickets to the Spamalot Broadway RevivalAugust 9, 2023 | finance.yahoo.comBrainsWay Reports Second Quarter 2023 Financial Results and Operational HighlightsAugust 6, 2023 | washingtonpost.com‘Spamalot’ to be first Kennedy Center production on Broadway in yearsAugust 3, 2023 | finance.yahoo.comBrainsWay Announces Publication of Three New Deep TMS Research PublicationsJuly 28, 2023 | nbcnews.comBroadway union reaches tentative deal with management, averting a strikeJuly 26, 2023 | finance.yahoo.comBrainsWay to Report Second Quarter 2023 Financial Results on August 9, 2023July 11, 2023 | baystreet.caBrainsWay Expands into IndiaJuly 11, 2023 | finance.yahoo.comBrainsWay Accelerates International Expansion in IndiaJune 23, 2023 | nbcnews.comTony nominee Emilio Sosa: From sketching in the South Bronx to dressing BroadwayJune 21, 2023 | finance.yahoo.comBrainsWay Announces Significant Expansion in Western and Central U.S.June 5, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for BrainsWayJune 5, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Brainsway (BWAY)May 23, 2023 | markets.businessinsider.comBrainsWay Appoints Ido Marom To Succeed Scott Areglado As CFOMay 23, 2023 | msn.comBrainsWay appoints CFOMay 23, 2023 | finance.yahoo.comBrainsWay Announces Appointment of Ido Marom as CFOMay 18, 2023 | markets.businessinsider.comBrainsWay - Aiming For Revenue Growth And ProfitabilityMay 17, 2023 | msn.comBrainsWay: Q1 Earnings InsightsMay 16, 2023 | msn.comEarnings Outlook For BrainsWaySee More Headlines Receive BWAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BrainsWay and its competitors with MarketBeat's FREE daily newsletter. Email Address BWAY Company Calendar Last Earnings8/09/2023Today9/26/2023Next Earnings (Estimated)11/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BWAY CUSIPN/A CIK1505065 Webwww.brainsway.com Phone(722) 582-4030FaxN/AEmployees134Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.67 High Stock Price Forecast$12.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+58.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,350,000.00 Net Margins-50.67% Pretax Margin-49.23% Return on Equity-29.12% Return on Assets-20.52% Debt Debt-to-Equity RatioN/A Current Ratio6.98 Quick Ratio6.54 Sales & Book Value Annual Sales$27.18 million Price / Sales2.58 Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book1.53Miscellaneous Outstanding Shares16,600,000Free Float13,445,000Market Cap$70.05 million OptionableNot Optionable Beta0.96 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Hadar Levy (Age 49)Chief Exec. Officer Comp: $470.16kMr. Avner Hagai (Age 67)Founder & Director Comp: $47.37kProf. Abraham Zangen (Age 53)Co-Founder, Member of Scientific Advisory Board & Director Comp: $77.2kMr. Christopher J. Boyer Ph.D. (Age 45)VP of Global Marketing Comp: $337.95kDr. Yiftach Roth Ph.D. (Age 52)Founder & Chief Scientific Officer Mr. Ido MaromChief Financial OfficerMr. Menachem C. Klein Esq.VP, Gen. Counsel & Corp. Sec.Dr. Aron TendlerChief Medical OfficerMore ExecutivesKey CompetitorsDelcath SystemsNASDAQ:DCTHLucid DiagnosticsNASDAQ:LUCDInspireMDNYSE:NSPRRosecliff Acquisition Corp INASDAQ:RCLFPro-DexNASDAQ:PDEXView All CompetitorsInstitutional OwnershipWorth Venture Partners LLCBought 317,598 shares on 8/15/2023Ownership: 1.916%Citadel Advisors LLCBought 4,747 shares on 8/15/2023Ownership: 0.367%Renaissance Technologies LLCBought 12,556 shares on 8/11/2023Ownership: 0.265%Psagot Value Holdings Ltd. Israel Bought 12,000 shares on 8/3/2023Ownership: 0.447%Good Life Advisors LLCBought 20,720 shares on 7/11/2023Ownership: 0.234%View All Institutional Transactions BWAY Stock - Frequently Asked Questions Should I buy or sell BrainsWay stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BrainsWay in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BWAY shares. View BWAY analyst ratings or view top-rated stocks. What is BrainsWay's stock price forecast for 2023? 3 brokerages have issued twelve-month price targets for BrainsWay's shares. Their BWAY share price forecasts range from $3.00 to $12.00. On average, they anticipate the company's stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 58.0% from the stock's current price. View analysts price targets for BWAY or view top-rated stocks among Wall Street analysts. How have BWAY shares performed in 2023? BrainsWay's stock was trading at $2.47 at the beginning of 2023. Since then, BWAY stock has increased by 70.9% and is now trading at $4.22. View the best growth stocks for 2023 here. Are investors shorting BrainsWay? BrainsWay saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 82,800 shares, an increase of 268.0% from the August 15th total of 22,500 shares. Based on an average daily volume of 50,000 shares, the days-to-cover ratio is presently 1.7 days. View BrainsWay's Short Interest. When is BrainsWay's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 15th 2023. View our BWAY earnings forecast. How were BrainsWay's earnings last quarter? BrainsWay Ltd. (NASDAQ:BWAY) released its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.12. The company had revenue of $7.83 million for the quarter, compared to analysts' expectations of $7.03 million. BrainsWay had a negative net margin of 50.67% and a negative trailing twelve-month return on equity of 29.12%. What other stocks do shareholders of BrainsWay own? Based on aggregate information from My MarketBeat watchlists, some companies that other BrainsWay investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Pfizer (PFE), Neuronetics (STIM), Boingo Wireless (WIFI), Eastman Chemical (EMN), Enbridge (ENB) and Energy Transfer (ET). When did BrainsWay IPO? (BWAY) raised $30 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 2,500,000 shares at $11.94 per share. Cantor served as the underwriter for the IPO. What is BrainsWay's stock symbol? BrainsWay trades on the NASDAQ under the ticker symbol "BWAY." Who are BrainsWay's major shareholders? BrainsWay's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Worth Venture Partners LLC (1.92%), Psagot Value Holdings Ltd. Israel (0.45%), Citadel Advisors LLC (0.37%), Renaissance Technologies LLC (0.27%) and Good Life Advisors LLC (0.23%). How do I buy shares of BrainsWay? Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BrainsWay's stock price today? One share of BWAY stock can currently be purchased for approximately $4.22. How much money does BrainsWay make? BrainsWay (NASDAQ:BWAY) has a market capitalization of $70.05 million and generates $27.18 million in revenue each year. The company earns $-13,350,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. How many employees does BrainsWay have? The company employs 134 workers across the globe. How can I contact BrainsWay? BrainsWay's mailing address is 19 HARTUM STREET BYNET BUILDING 3RD FL Har HaHotzvim, Jerusalem L3, 9777518. The official website for the company is www.brainsway.com. The company can be reached via phone at (722) 582-4030 or via email at hadarl@brainsway.com. This page (NASDAQ:BWAY) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BrainsWay Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.